Minimal effective dose of oral bedaquiline and activity of a long acting formulation of bedaquiline in the murine model of leprosy Bedaquiline for the treatment of leprosy

Author:

Chauffour AurélieORCID,Lounis Nacer,Andries Koen,Jarlier Vincent,Veziris Nicolas,Aubry Alexandra

Abstract

AbstractBackgroundBedaquiline (BDQ), by targeting the electron transport chain and having a long half-life, is a good candidate to simplify leprosy treatment. Our objectives were to (i) determine the minimal effective dose (MED) of oral BDQ, (ii) evaluate the benefit of adding another inhibitor of the respiratory chain to oral BDQ (i.e.clofazimine (CFZ)) and (iii) evaluate the benefit of an intramuscular injectable long-acting formulation of BDQ (intramuscular BDQ; BDQ-LA IM), in a murine model of leprosy.Methodology/ Principal FindingsTo determine the MED of oral BDQ and the benefit of adding CFZ, 100 four-week-old female nude mice were inoculated in the footpads with 5.103bacilli ofM. lepraestrain THAI53. Mice were randomly allocated into: 1 untreated group, 5 groups treated with oral BDQ (0.10 to 25 mg/kg), 3 groups treated with CFZ 20 mg/kg alone or combined with oral BDQ 0.10 or 0.33 mg/kg, and 1 group treated with rifampicin (RIF) 10 mg/kg. Mice were treated 5 days a week during 24 weeks.To evaluate the benefit of the BDQ-LA IM, 340 four-week-old female Swiss mice were inoculated in the footpads with 5.103to 5.101bacilli (or 5.100for the untreated control group) ofM. lepraestrain THAI53. Mice were randomly allocated into the following 11 groups treated with a single dose (SD) or 3 doses (3D) 24h after the inoculation: 1 untreated group, 2 treated with RIF 10 mg/kg SD or 3D, 8 treated with oral BDQ or BDQ-LA IM 2 or 20 mg/kg, SD or 3D.Twelve months later, mice were sacrificed andM. lepraebacilli enumerated in the footpad. All the footpads became negative with BDQ at 3.3 mg/kg. The MED of oral BDQ againstM. lepraein this model is therefore 3.3 mg/kg. The addition of CFZ to a dose of BDQ 10-fold lower than this MED increased the bactericidal activity of BDQ suggesting synergies between both drugs. The BDQ-LA IM displayed similar or lower bactericidal activity than the oral BDQ.ConclusionWe demonstrated that the MED of oral BDQ againstM. lepraewas 3.3 mg/kg in mice and the addition of CFZ to oral BDQ may improve the efficacy of BDQ. BDQ-LA IM was similar or less active than oral BDQ at equivalent dosing and frequency but should be tested at higher dosing in order to reach equivalent exposure in further experiments.

Publisher

Cold Spring Harbor Laboratory

Reference29 articles.

1. Asia RO for S-E, Organization WH. Global leprosy strategy 2016-2020: accelerating towards a leprosy-free world - 2016 operational manual. WHO Regional Office for South-East Asia; 2016. Available: https://apps.who.int/iris/handle/10665/250119

2. WHO Study Group on Chemotherapy of Leprosy for Control Programmes, World Health Organization. Chemotherapy of leprosy for control programmes: report of a WHO study group [meeting held in Geneva from 12 to 16 October 1981]. 1982. Available: https://apps.who.int/iris/handle/10665/38984

3. World Health Organization . Towards zero leprosy. Global leprosy (Hansen’s Disease) strategy 2021–2030. World Health Organization; 2021. Available: https://apps.who.int/iris/handle/10665/340774

4. Global leprosy (Hansen disease) update, 2020: impact of COVID-19 on the global leprosy control. [cited 29 Nov 2021]. Available: https://www.who.int/publications-detail-redirect/who-wer9636-421-444

5. Primary Dapsone-resistant Leprosy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3